[PDF][PDF] Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
LS van der Schoota, S Atalaya… - The road towards …, 2023 - repository.ubn.ru.nl
DEAR EDITOR, Previous studies showed that dose reduction (DR) of adalimumab,
etanercept and ustekinumab is successful in a substantial number of patients with psoriasis …
etanercept and ustekinumab is successful in a substantial number of patients with psoriasis …
Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting
Y Lang, B Wu, Z Sun, E Ye, G Dou… - Patient preference and …, 2022 - Taylor & Francis
Objective Assessments of patients' preferences can support in clinical decision-making
regarding biologic therapies for psoriasis. Our objective was to investigate patient …
regarding biologic therapies for psoriasis. Our objective was to investigate patient …
[PDF][PDF] ATTITUDES AND BEHAVIOUR OF DERMATOLOGISTS WORLDWIDE TOWARDS DOSE REDUCTION OF BIOLOGICS IN PSORIASIS
ME van Muijen, LS van der Schoot… - … THE SURFACE OF …, 2022 - repository.ubn.ru.nl
Dose reduction (DR) of biologics, where possible, seems promising for more efficient use of
expensive biologics. For implementation of DR strategies, it is essential to get insight in …
expensive biologics. For implementation of DR strategies, it is essential to get insight in …
[HTML][HTML] Wetenschap-Dosisreductie van biologics bij psoriasis: stand van zaken en perspectieven (2021-07)
LS van der Schoot, ME van Muijen, J van den Reek… - nvdv.nl
In dit artikel willen wij de lezers informeren over de opmars van dosisreductie van biologics
bij psoriasis, en een update geven over (inter) nationaal onderzoek naar dit onderwerp. Ook …
bij psoriasis, en een update geven over (inter) nationaal onderzoek naar dit onderwerp. Ook …
[PDF][PDF] Dosisreductie van biologics bij psoriasis: stand van zaken en perspectieven
LS van der Schoot, ME van Muijen, J van den Reek… - Vliegende fakirs - nvdv.nl
Met het beschikbaar komen van biologics is het therapeutisch arsenaal voor de
behandeling van psoriasis sterk gegroeid in de laatste twee decennia. Momenteel zijn er 11 …
behandeling van psoriasis sterk gegroeid in de laatste twee decennia. Momenteel zijn er 11 …
Allungamento del tempo di somministrazione dei farmaci biologici in pazienti con psoriasi stabilizzata come raggiungimento della" sensazione di guarigione": studio …
M Magnano - 2019 - amsdottorato.unibo.it
La psoriasi è una malattia infiammatoria cronica cutanea che, a seconda della gravità, può
essere classificata in lieve, moderata e severa. Per le forme severe, sono stati recentemente …
essere classificata in lieve, moderata e severa. Per le forme severe, sono stati recentemente …
Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis …
E Jáuregui, W Bautista, A Beltrán, O Felipe… - Revista Colombiana de …, 2019 - Elsevier
Objective The objective of this study was to establish recommendations for the reduction and
discontinuation of biological disease-modifying antirheumatic drugs, with the aim of …
discontinuation of biological disease-modifying antirheumatic drugs, with the aim of …
[引用][C] Down-Titration of Infliximab: The Real-Life Use in Psoriatic Patients
JDD Corner, TL Series, ID Atlas - jddonline.com
[引用][C] su riviste recensite da indici internazionali
S Donato, G Girolomoni, G Micali, E Moggio, A Parodi… - Eur J Dermatol, 2017